As global markets grapple with energy price volatility and geopolitical tensions, Asian equities have been influenced by these broader economic pressures, prompting investors to reassess valuations across the region. In this environment, identifying stocks trading below their estimated intrinsic value can provide opportunities for investors seeking potential growth amidst uncertainty.
Top 10 Undervalued Stocks Based On Cash Flows In Asia
| Name |
Current Price |
Fair Value (Est) |
Discount (Est) |
|---|---|---|---|
| Softcare (SEHK:2698) |
HK$33.00 |
HK$64.43 |
48.8% |
| Sinomine Resource Group (SZSE:002738) |
CN¥74.59 |
CN¥144.23 |
48.3% |
| SILICON2 (KOSDAQ:A257720) |
₩40000.00 |
₩76894.87 |
48% |
| SHIFT (TSE:3697) |
¥677.70 |
¥1302.04 |
48% |
| Sailvan Times (SZSE:301381) |
CN¥19.66 |
CN¥38.44 |
48.8% |
| Rayhoo Motor DiesLtd (SZSE:002997) |
CN¥30.36 |
CN¥59.12 |
48.6% |
| JAC Recruitment (TSE:2124) |
¥861.00 |
¥1713.75 |
49.8% |
| Cypress Holdings (TSE:428A) |
¥876.00 |
¥1719.66 |
49.1% |
| AViC (TSE:9554) |
¥1420.00 |
¥2725.22 |
47.9% |
| Advanced Process Systems (KOSDAQ:A265520) |
₩20250.00 |
₩39661.81 |
48.9% |
Underneath we present a selection of stocks filtered out by our screen.
Angelalign Technology
Overview:Angelalign Technology Inc. is an investment holding company that focuses on researching, designing, manufacturing, selling, and marketing clear aligner treatment solutions in China and internationally, with a market cap of approximately HK$13.21 billion.
Operations:Angelalign Technology generates its revenue primarily from the research, design, manufacture, sale, and marketing of clear aligner treatment solutions in both domestic and international markets.
Estimated Discount To Fair Value:15.7%
Angelalign Technology appears undervalued, trading at HK$77.35 against an estimated future cash flow value of HK$91.76. Despite significant recent earnings growth of 134.7%, its dividend yield of 7.66% is not well covered by free cash flows, raising sustainability concerns. The company forecasts robust annual profit growth of 23.9%, outpacing the Hong Kong market's average, driven by increased adoption and operational efficiencies in their clear aligner solutions amidst ongoing legal challenges in Europe.
Fujian Wanchen Food Group
Overview:Fujian Wanchen Biotechnology Co., Ltd., along with its subsidiaries, focuses on the research, development, cultivation, production, and sale of edible fungi both in China and internationally, with a market cap of CN¥37.20 billion.
Operations:The company's revenue is primarily derived from its Bulk Snacks segment, which generated CN¥50.86 billion, and its Edible Fungus segment, which contributed CN¥603.76 million.
Estimated Discount To Fair Value:39.4%
Fujian Wanchen Food Group is trading at CN¥194.47, significantly below its estimated future cash flow value of CN¥320.72, suggesting undervaluation. Recent earnings results showed substantial growth, with net income rising to CN¥1.34 billion from CN¥293.52 million the previous year, and earnings per share increasing markedly. Analysts expect annual profit growth of 26.3%, slightly trailing the broader Chinese market's growth rate but still robust in comparison to historical performance trends within the sector.
-
Dive into the specifics of Fujian Wanchen Food Group here with our thorough financial health report.
GMO Payment Gateway
Overview:GMO Payment Gateway, Inc., along with its subsidiaries, offers payment-related and financial services both in Japan and internationally, with a market cap of ¥638.88 billion.
Operations:The company's revenue is primarily derived from its Payment Processing Business at ¥63.10 billion, followed by the Money Service Business at ¥19.97 billion and the Payment Enhancement Business at ¥1.78 billion.
Estimated Discount To Fair Value:11.3%
GMO Payment Gateway, trading at ¥8,407, is priced below its future cash flow value of ¥9,473.91. Analysts forecast revenue growth at 11.4% annually and earnings growth at 13.4%, both outpacing the Japanese market averages. Despite being dropped from the S&P Japan Mid Cap 100 index, GMO's strategic partnership with Mesirow enhances its structured finance capabilities and credit investment platform in Asia, potentially strengthening future cash flows and financial position.
Where To Now?
-
Navigate through the entire inventory of 236 Undervalued Asian Stocks Based On Cash Flows here.
-
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
-
Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.
Interested In Other Possibilities?
-
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
-
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
-
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SEHK:6699 SZSE:300972 and TSE:3769.
This article was originally published by Simply Wall St .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
